MedTrace Logo

Multimodality Cardiac Imaging for Disease Progression in ATTR-CM

NCT07112066 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2025-12-09

No results posted yet for this study

Summary

The goal of this clinical trial is to investigate whether new imaging techniques can help us to better understand the cardiac amyloidosis. The disease can be slowed down with various medications (e.g., tafamidis, acoramidis, or vutrisiran). However, treatment is not effective in all patients-in about one-third of cases, the disease continues to progress. So far, we know little about the exact causes of this and what biological changes occur in the heart muscle.

The main question it aims to answer is:

Will new imaging techniques help us understand the course of the cardiac amyloidosis?

Participants will have additional examinations:

* At the beginning of the study: one additional heart ultrasound examination, one cardiac MRI and one cardiac PET, blood examination during the regular examination, questionnaires.
* After a year: one additional heart ultrasound examination, one cardiac MRI and one cardiac PET, blood examination during the regular examination.

Time required:

* Heart ultrasound examination: 5-10 Minutes
* Cardiac MRI: 2 hours
* Cardiac PET: 2 hours
* Questionnaires: 5-10 Minutes.

Conditions

  • Amyloidosis Cardiac

Interventions

DIAGNOSTIC_TEST

FAPI tracer

18F-FAPI-74 PET/CT, cardiac MRI, echocardiography and blood sample for BMP5 serum concetration is performed at baseline and 12-month follow-up.

Sponsors & Collaborators

  • Olga Mayenfisch Stiftung, Zurich, Switzerland

    collaborator UNKNOWN

  • University of Zurich

    collaborator OTHER

  • Dominik Benz

    lead OTHER

Principal Investigators

  • Dominik C Benz, MD · Universität Zürich

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-10-20
Primary Completion
2027-06-30
Completion
2027-06-30

Countries

  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07112066 on ClinicalTrials.gov